Integra LifeSciences plans to divest neurosurgery assets to Natus: 5 things to know

Megan Wood -   Print  | Email

Integra LifeSciences plans to divest certain assets of its neurosurgery business to Natus.

Here are five things to know:


1. Under the definitive agreement, Natus would purchase Integra's neurosurgery assets in a $47.5 million all cash transaction. The company plans to use cash on hand and from its credit facility.


2. This acquisition would come to fruition when Integra finalizes its Johnson & Johnson's Codman Neurosurgery acquisition.


3. The agreement states Natus would acquire Integra's Camino ICP monitoring product line.


4. Natus would also gain U.S. rights associated with Integra's fixed pressure shunts and Codman's DURAFORM dural graft implant, standard EVD catheters and CSF collection systems.


5. Final regulatory approvals are still pending for both the Codman Neurosurgery and Integra neurosurgery asset acquisitions. The companies anticipate closing the transactions in October.


More articles on devices:
Medtronic, NuVasive, Life Spine & more: 14 device company notes
Medtronic, Smith & Nephew & more: 9 device company mergers, acquisitions and agreements
Global hip reconstruction devices to grow $126.6M per annum through 2022 — 6 observations


© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.